Table 3.
Serum Antibody | Trastuzumab-Negative Control | Individual Patient OD (415 nm) Values to Human Recombinant HER2 by Patient |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
1A | 1B | 1D | 2A | 4A | 4B | 4C | 4D | 4E | 4F | ||
OD value, 415 nm | −0.2 | 0.589 | 0.786 | 0.225 | 0.419 | 0.23 | 0.86 | 0.427 | 0.695 | 0.361 | 0.468 |
NOTE. Individual patients A through F are in cohort 4. Results of each patient in dose level 4 (ie patients 4A through 4F) and those with a clinical response (ie, patients 1A, 1B, 1D, and 2A) are shown, using a 1:16 dilution of patient sera. The y-axis represents the absorbance after subtracting patient presera (ie, day 1) value.
Abbreviations: IgG, immunoglobulin G; HER-2, human epidermal growth factor receptor 2; ELISA, enzyme-linked immunosorbent assay; OD, optical density.